BetterLife Pharma Inc. (CSE:BETR)

Market Cap	157.56M +1,242.3%
Revenue (ttm)	n/a
Net Income	-3.48M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	314,343
Open	0.2800
Previous Close	0.2700
Day's Range	0.2550 - 0.2800
52-Week Range	0.0400 - 0.4600
Beta	0.22
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 30, 2026

About BetterLife Pharma

BetterLife Pharma Inc., a biotechnology company, engages in the development of psychedelic-derived compounds. It focuses on developing and commercializing BETR-001, a non-hallucinogenic and non-controlled LSD derivative to treat neuro-psychiatric and neurological disorders. Its products also comprise MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and MM-003, a patent pending proprietary interferon alpha-2b inhalation formulation. The company was formerly known as Pivot Pharmaceuticals...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 7
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: BETR

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error